SYF vs TBPH · rev $11.19B vs P/E 7.5, rev $38.4M
SYF (SYF) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
SYF (SYF) common stock.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported SYF revenue for 2026-06-30 was $11.19B. Net income was $1.69B. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. SYF currently screens at market cap $0.
Latest reported TBPH revenue for 2026-06-30 was $38.4M. Net income was -$10.8M. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
SYF currently screens at market cap $0. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the SYF and TBPH stock pages for the full models.
Not investment advice.